Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Characterisation of EGFR and KRAS mutations in non-small cell lung cancer
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
2010 (English)Independent thesis Basic level (degree of Bachelor), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Background: Lung cancer is the leading cause of cancer-related death and one of the most common cancer types worldwide. Epidermal growth factor receptor (EGFR) has been shown to be an important therapeutic target in non-small cell lung cancer. Kirsten rat sarcoma viral oncogene homologue (KRAS) is a downstream signalling molecule in the EGFR pathway. Lung cancer patients with EGFR mutations respond to tyrosine EGFR inhibitor therapy, in contrast, patients with KRAS mutations do not benefit of such treatment.

Methods: This study investigates the frequency of EGFR and KRAS mutations in non-small cell lung cancer patients. Fifty-one lung cancer patients with primary non-small cell lung cancer diagnosed between 1995 and 2005 in the Uppsala-Örebro region were analysed by Sanger sequencing and Pyrosequencing to determine the mutation status of these genes.

Results: Five EGFR mutations were found in four patients (8%), two deletions in exon 19, one point mutation in exon 20 and two point mutations in exon 21. KRAS mutations were found in 12 patients (24%), ten codon 12 mutations and two codon 61 mutations.

Conclusions: This study confirms previous observations regarding the frequency of EGFR and KRAS mutations in non-small cell lung cancer. Mutations in EGFR and KRAS were mutually exclusive, indicating that both mutations present relevant tumorigenic genomic aberrations.

Place, publisher, year, edition, pages
2010. , p. 17
Keywords [en]
NSCLC, mutation, TKI, Sanger sequencing and Pyrosequencing
National Category
Medical Genetics
Identifiers
URN: urn:nbn:se:uu:diva-126041OAI: oai:DiVA.org:uu-126041DiVA, id: diva2:321680
Presentation
(English)
Uppsok
Medicine
Supervisors
Examiners
Available from: 2010-06-04 Created: 2010-06-01 Last updated: 2018-01-12Bibliographically approved

Open Access in DiVA

fulltext(235 kB)1668 downloads
File information
File name FULLTEXT01.pdfFile size 235 kBChecksum SHA-512
afa2e03145d3fca049ce35056699af6e7f060b1ce7c5b4606c6cf23deec25b38c2833cc7b14ff62cfeb0f09fddda3bb807e348cdaa7ebf43ecfc485235dbb721
Type fulltextMimetype application/pdf

Search in DiVA

By author/editor
Martinsson, Caroline
By organisation
Department of Medical Biochemistry and Microbiology
Medical Genetics

Search outside of DiVA

GoogleGoogle Scholar
Total: 1668 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 809 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf